Clinical Trials

Seattle Genetics, Inc. and Astellas Pharma Inc. announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with checkpoint inhibitor (CPI) therapy. The EV-201 study will assess the antitumor…
BrainStorm Cell Therapeutics Inc announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn® for the treatment of ALS at the Massachusetts General Hospital and UC Irvine Medical Center in California. The trial is expected to enroll approximately 200 patients and will be conducted…
Exelixis, Inc. announced that its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has reported positive top-line results from a phase 3 pivotal trial of esaxerenone (INN; code name CS-3150), a product of the companies’ prior research collaboration, in patients with essential hypertension in Japan. With the trial achieving its primary…
Aurigene Discovery Technologies Ltd, a wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd and Curis, Inc. have announced plans to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India. This was announced following the presentation of preliminary data from the initial 34…
Novartis announced, first of its kind phase III data showing Cosentyx (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland.  …
Page 1 of 27

Subscribe To Our Newsletter

Security Q:How many eyes has a typical person? (ex: 1)
Name:
Email: